Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Moodys
Citi
Queensland Health
Colorcon
Express Scripts
Cipla
Cantor Fitzgerald
Novartis
AstraZeneca

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,125,560

« Back to Dashboard

Which drugs does patent 7,125,560 protect, and when does it expire?


Patent 7,125,560 protects TOPAMAX and TOPAMAX SPRINKLE and is included in one NDA. There have been zero Paragraph IV challenges on Topamax and Topamax Sprinkle

Protection for TOPAMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in thirty-one countries.

Summary for Patent: 7,125,560

Title:Pharmaceutical composition of topiramate
Abstract:The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.
Inventor(s): Thakur; Madhav S. (North Wales, PA), Kotwal; Pramod M. (Blue Bell, PA), Gibbs; Irwin S. (Huntington Valley, PA)
Assignee: Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Application Number:10/748,764
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Janssen PharmsTOPAMAXtopiramateCAPSULE;ORAL020844-001Oct 26, 1998ABRXYesNo► Subscribe► Subscribe► SubscribeY
Janssen PharmsTOPAMAXtopiramateCAPSULE;ORAL020844-002Oct 26, 1998ABRXYesYes► Subscribe► Subscribe► SubscribeY
Janssen PharmsTOPAMAX SPRINKLEtopiramateCAPSULE;ORAL020844-003Oct 26, 1998DISCNNoNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,125,560

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,696,091 Pharmaceutical composition of topiramate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,125,560

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Africa9901716► Subscribe
World Intellectual Property Organization (WIPO)9944581► Subscribe
Ukraine65607► Subscribe
Taiwan590778► Subscribe
Turkey200002541► Subscribe
Slovakia13062000► Subscribe
Slovakia285440► Subscribe
Portugal1066027► Subscribe
Slovenia1066027► Subscribe
Poland194559► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Julphar
Cipla
Teva
McKesson
Daiichi Sankyo
Novartis
Mallinckrodt
Deloitte
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot